利妥昔单抗对自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞的影响

陶书超

doi:10.13201/j.issn.1004-2806-b.2019.10.020

利妥昔单抗对自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞的影响

陶书超^,

- 枣阳市第一人民医院输血科(湖北枣阳, 441299)

详细信息

通讯作者: 陶书超,E-mail:452510985@qq.com

中图分类号: R556

收稿日期: 2019-07-25

Influence of rituximab on Th1/Th2,Th3/Tr1 cells of patients with autoimmune hemolytic anemia

TAO Shuchao^,

- Department of Blood Transfusion, Zaoyang First People's Hospital, Zaoyang, 441299, China

More Information

Corresponding author: TAO Shuchao, E-mail: 452510985@qq.com

Received Date: 25 July 2019

摘要

摘要: 目的:探讨利妥昔单抗对自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞的影响。方法:以2017-06—2018-06收治的76例自身免疫性溶血性贫血患者为对象,按电脑数字表法随机分为2组,每组各38例,对照组予以常规治疗,试验组在常规治疗基础上予以利妥昔单抗治疗,对比2组疗效及外周血Th1/Th2、Th3/Tr1细胞情况。结果:治疗后,试验组Th1/Th2较对照组低,Th3/Tr1相关细胞(白细胞介素10、转化生长因子-β1)较对照组高,差异有统计学意义(P＜0.05);治疗后,试验组血红蛋白较对照组高,网织红细胞、总胆红素较对照组低,差异有统计学意义(P＜0.05);试验组总有效率(84.74%)较对照组(76.32%)高,差异有统计学意义(P＜0.05)。结论:利妥昔单抗可有效改善自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞及相关血清学指标,进而提升临床疗效。
- 利妥昔单抗 /
- 自身免疫性溶血性贫血 /
- 治疗 /
- Th1/Th2 /
- Th3/Tr1
Abstract: Objective:To investigate the influence of rituximab on Th1/Th2,Th3/Tr1 cells of the patients with autoimmune hemolytic anemia.Method:A total of 76 patients with autoimmune hemolytic anemia were admitted to our hospital from June 2017 to June 2018 as the objects,according to the computer digital table method,these patients were randomly divided into two groups,each with 38 patients.The control group received routine treatment,and the experimental group received rituximab on the basis of conventional treatment.The efficacy and the peripheral blood Th1/Th2,Th3/Tr1 cells were compared between the two groups.Result:After treatment,the Th1/Th2 in the experimental group was lower than that in the control group,and the Th3/Tr1 related cells(including interleukin-10 and transforming growth factor-β1)were higher than those of the control group,with statistically significant(P＜0.05).After treatment,the hemoglobin of the experimental group was higher than that of the control group,while the reticulocytes and total bilirubin were lower than those of the control group,with statistically significant(P＜0.05).The total effective rate of the experimental group was 84.74%,which was higher than that of the control group(76.32%),with statistically significant(P＜0.05).Conclusion:Rituximab can effectively improve Th1/Th2,Th3/Tr1 cells and related serological markers in peripheral blood of patients with autoimmune hemolytic anemia,and improve clinical efficacy.
- rituximab /
- autoimmune hemolytic anemia /
- treatment /
- Th1/Th2 /
- Th3/Tr1

HTML全文

参考文献(12)

[1]	Narurkar R,Mamorskadyga A,Nelson JC,et al.Autoimmune hemolytic anemia associated with babesiosis[J].Biomark Res,2017,5:14-14.
[2]	陈苗,庄俊玲.低剂量利妥昔单抗治疗温抗体型自身免疫性溶血性贫血的系统评价[J].基础医学与临床,2017,37(10):1444-1448.
[3]	中华医学会血液学分会红细胞疾病(贫血)学组.自身免疫性溶血性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(4):265-267.
[4]	苏万祥.不同输血方法在自身免疫性溶血性贫血患者中的应用分析[J].临床检验杂志(电子版),2017,6(3):76-77.
[5]	黎海江,冯学冠,符晓玲,等.血液置换联合洗涤红细胞输注对自身免疫性溶血性贫血患者的治疗效果[J].山东医药,2018,58(13):90-92.
[6]	Ogawa K,Ito J,Fujimoto D,et al.Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab:a case report[J].Invest New Drugs,2018,36:1-4.
[7]	曲莹莹,邢莉民,邵宗鸿.T淋巴细胞在自身免疫性溶血性贫血发病机制中的作用[J].国际输血及血液学杂志,2017,40(5):450-454.
[8]	金伟媚,江锦红,方炳木.利妥昔单抗联合常规治疗自身免疫性溶血性贫血的疗效观察[J].药物流行病学杂志,2017,13(4):9-12.
[9]	邢莉民,徐文艳,段宁宁,等.自身免疫性溶血性贫血/Evans综合征患者外周血CD4+CD69+T细胞的临床意义[J].中华内科杂志,2018,57(9):656-660.
[10]	Yoshida M,Marumo Y,Naitoh I,et al.Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis:A Case Report and Review of the Literature[J].Intern Med,2018,57:1725-1732.
[11]	陈艳欣,郑晓云,刘庭波,等.利妥昔单抗联合CHOP与单用CHOP方案治疗初治弥漫大B细胞淋巴瘤疗效及安全性对比[J].临床血液学杂志,2015,28(9):760-763.
[12]	代湘云,吴涛,毛东锋,等.利妥昔单抗在血液系统疾病中的应用现状[J].中华全科医师杂志,2018,17(10):840-842.